前列腺癌立体定向体部放疗中磁共振成像与计算机断层扫描引导的比较:MIRAGE随机临床试验的2年结局
MIRAGE是一项3期随机临床试验,比较MRI引导与CT引导下前列腺癌立体定向体部放疗(SBRT)采用积极边缘缩减(AMR)的2年毒性。二次分析显示,MRI引导组2年晚期≥2级泌尿生殖毒性累积发生率为27%,CT引导组为51%(p=0.004);胃肠道毒性分别为1.4%与9.5%(p=0.025)。MRI引导与肠道功能和性功能临床相关恶化的 odds 显著降低相关。
要点
- MRI引导较CT引导显著降低2年晚期≥2级泌尿生殖毒性(27% vs 51%,p=0.004)。
- MRI引导较CT引导显著降低2年晚期≥2级胃肠道毒性(1.4% vs 9.5%,p=0.025)。
- MRI引导与肠道功能(OR 0.444)和性功能(OR 0.366)恶化 odds 降低相关。
核心结论
- 这些发现支持以下假设:使用MRI进行积极计划以实现前列腺SBRT边缘缩减,可在2年随访期间持续减少毒性。
研究设计与样本
- MIRAGE是一项3期随机临床试验(ClinicalTrials.gov注册号NCT04384770),本文为其二次分析,比较MRI引导与CT引导下前列腺癌SBRT采用积极边缘缩减(AMR)的2年医师评分或患者报告毒性。
主要发现
- 2年晚期≥2级泌尿生殖毒性累积发生率:MRI引导组27%(95%CI 19-39%)vs CT引导组51%(95%CI 41-63%),p=0.004。
- 2年晚期≥2级胃肠道毒性累积发生率:MRI引导组1.4%(95%CI 0.2-9.6)vs CT引导组9.5%(95%CI 4.6-19),p=0.025。
- 累积逻辑回归显示,MRI引导SBRT与根据EPIC-26评分肠道功能临床相关恶化的 odds 显著降低相关(OR 0.444,95%CI 0.209-0.942;p=0.035)。
- MRI引导SBRT与根据SHIM评分性功能临床相关恶化的 odds 显著降低相关(OR 0.366,95%CI 0.148-0.906;p=0.03)。
- 其他生活质量指标恶化的 odds 无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) guidance for aggressive margin-reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer, to determine whether AMR with MRI guidance significantly reduced 2-yr physician-scored or patient-reported toxic effects in comparison to CT guidance. The cumulative incidence of 2-yr physician-scored toxicity, defined as grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxic effects according to Common Terminology Criteria for Adverse Events v4.03, were lower with MRI guidance. Cumulative incidence rates of late grade ≥2 toxicity at 2 yr with MRI-guided versus CT-guided SBRT were 27% (95% confidence interval [CI] 19-39%)] versus 51% (95% CI 41-63%) for GU toxicity (p = 0.004), and 1.4% (95% CI 0.2-9.6) versus 9.5% (95% CI 4.6-19) for GI toxicity (p = 0.025). Cumulative logistic regression revealed that MRI-guided SBRT was associated with significantly lower odds of a clinically relevant deterioration in bowel function according to the Expanded Prostate Cancer Index Composite-26 score (odds ratio 0.444, 95% CI 0.209-0.942; p = 0.035) and in the Sexual Health Inventory in Men score (odds ratio 0.366, 95% CI 0.148-0.906; p = 0.03). There were no significant differences in the odds of a deterioration for other quality-of-life metrics. These findings support the hypothesis that aggressive planning for margin reduction for prostate SBRT using MRI leads to continued reductions in toxic effects over 2-yr follow-up. This trial is registered on ClinicalTrials.gov Identifier as NCT04384770.
引用
- Kishan AU, Lamb JM, Wilhalme H, et al. Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial. Eur Urol. 2024. PMID: 39537438. doi:10.1016/j.eururo.2024.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。